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Original Article: Applying Nanoparticles in the Treat-
ment of Viral Infections and Toxicological Considerations
Background: Despite the tremendous progress in human medicine, viral infections can cause 
death in them. Due to the high prevalence of viruses, it is required to develop novel treatment 
strategies and provide the site-specific delivery of antiviral agents at the viral reservoirs.
Objectives: Particle size is a vital physical characteristic that can affect the bioavailability and 
circulation time of nanoparticles. The ratio of large surface area and volume of nanoparticle 
could enhance the solubility of poorly soluble drug compounds. 
Methods: Therefore, the optimum surface charge of the nanoparticle with the possibility of 
encapsulation and large drug cargo, are some of the nanoformulation advantages of these 
agents.
Results: This study reviewed various nanocarriers and modern smart delivery technologies, 
such as liposomes and immunoliposomes, polymeric nanoparticles, nanoemulsions, 
nanosuspensions, dendrimers, solid lipid nanoparticles, and so on.
Conclusion: We aimed to overcome the problems of traditional formulations and resistance to 
currently available therapies in various infections. Moreover, the concerns about the potential 
toxicities of nanoparticles to humans have been raised; therefore, the present study has 
reviewed the toxicity effects of nanoparticles used in controlling viral infections. 
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Introduction
anomedicine, as a field of nanotechnology, 
has potential applications for tissue target-
ing, controlled release, increasing perme-
ability, and drug solubility with higher 
efficacy, improved safety and decreased 
toxicity [1]. The biopharmaceutical properties contain 
Absorption, Distribution, Metabolism, and Excretion 
(ADME), which are strongly associated with the physico-
chemical characteristics of drug formulation [2]. The use 
of nanomedicine offers some advantages that can improve 
the fate of drug molecules. Nanocarriers act as the trans-
porters of therapeutic drug moiety to the target tissue.
Interestingly, nanoparticle formulation can change the 
biochemical properties of drug molecules, causing sus-
tained/controlled release, modified pharmacokinetics, 
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and targeting specific sites of action in the cells. This can 
increase the effectiveness of treatment and decrease its 
complications [3]. Significant advancements are used 
in developing nanomedicine in the treatment of many 
diseases. Treating viral infections is among global chal-
lenges in a healthy society. Furthermore, it significantly 
impacts the health and economy status of millions of 
people and may cause diseases and death worldwide. 
Treating viral infections reduces drug’s efficacy with the 
development of drug resistance. This phenomenon is a 
threat to public health and increases the mortality and 
morbidity rates and medical costs [4].
When infectious virus particles (virions) attached to 
susceptible cells and interned them, viral infections are 
generated. Accordingly, the virions can spread locally or 
over long distances through blood flow, lymph, or neural 
routes. The spread of infectious viruses from cell to cell 
often involves the direct transfer of infectious particles 
into the extracellular environment. To spread the infec-
tion, it is necessary to transport viral particles within the 
neurons and spread to epithelial cells; however, the num-
ber of viruses transmitted between the cells during these 
events is unclear [5].
The most important advantages of nanocarriers that 
make them good candidates for antiviral drug delivery 
are their biochemical properties, such as small particle 
size [6], the ratio of large surface area to volume [7], and 
tunable surface charge; which facilitates the penetration 
of particles through the negative charge of cell mem-
brane [8]. Furthermore, nanocarriers can increase the 
bioavailability of encapsulated drug contents, improve 
the solubility and stability of the drug compounds in 
physiological conditions, facilitate take-up by phagocyt-
ic cells as viral  reservoirs, deliver the drug compound 
intracellular, reduce antiviral drug compound toxicities, 
delay the drug resistance, overcome the biological bar-
riers [e.g. Blood Brain Barrier (BBB) and blood test 
barrier] [9], improve cellular uptake, and increase drug 
delivery to the target sites [10]. This review study will 
discuss various recent investigations (past 10 years) on 
nanocarriers regarding antiviral drugs and vaccine deliv-
ery and their toxicities and other adverse effects.
Nano drug delivery systems for antiviral drugs
Liposomes 
Liposomes are efficient delivery systems for drug com-
pounds or biological entities. They are closed spherical 
vesicles, containing phospholipids and cholesterol. Li-
posomes can encapsulate hydrophilic, amphipathic, and 
lipophilic drug molecules into inner water phase or with-
in lipid leafleted. Liposomes, as carriers, could release 
their cargo (drug or antigen) in specific target sites. This 
nanocarrier can provide a focused antimicrobial innate 
and immune response against pathogens.
Moreover, it could be used as a novel agent for prophy-
laxis or therapy against microbial infections [11]. Small 
and single-lipid bilayer liposomes (20-100 nm diame-
ter), enclose a large aqueous core; they are ideally suited 
for the encapsulation of hydrophilic drug compounds/
antigens. In return, Multi Lamellar Vesicles (MLV) are 
characterized by the presence of two or more concen-
tric lipid bilayers (500-5000 nm diameter) that prefer-
entially entrap hydrophobic drug molecules. Liposomes 
structure forms a protective barrier, which can typically 
protect the cargo from degradation. It can also help them 
to release at the target cell or organ.
Liposomes are biocompatible and biodegradable and 
have low toxicity [12]. Despite many advantages, lipo-
some formulations have several significant issues. The 
first one is the elimination of liposomes from systemic 
blood circulation by the Reticuloendothelial System 
(RES) which phagocyte the se nanoparticles and causes 
the short plasma half-life times of these nanoformula-
tions [13]. Some studies suggested that more substantial 
size and negative charge at the liposomal surface will 
decrease the half-life of the liposomes [14]. Removing 
liposomes from the circulation by phagocytosis is di-
rectly associated with their diameter. MLV with diam-
eters from 500 to 5000 nm are quickly eliminated by 
phagocytes; whereas, Unilamellar Vesicles (ULV) with 
diameters between 20 and 50 nm are less internalized by 
macrophages [14].
Croci et al. argued that ivermectin cytotoxicity, when 
delivered via liposomes, was reduced up to 5 times, in 
comparison to free drugs. They reported a significant in-
crease in the antiviral activity of the liposomal forms of 
ivermectin. This nanocarrier can effectively inhibit the 
replication of dengue virus with half-maximal Effective 
Concentration (EC50) values. They found that the ad-
ministration of ivermectin by a liposomal formulation 
yielded higher Cmax and significantly faster absorption 
time. This finding suggested that applying liposomes 
could improve the in vivo efficacy of ivermectin. This 
technology can also improve the spectrum of ivermectin 
therapeutic activities [15]; it can be a promising starting 
point for the future development of liposomal nanocarri-
ers against pathogenic viruses.
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Local antiviral formulations have been produced with 
nano-liposomes technology. Liposomal gel, as the topi-
cal formulation of idoxuridine, was prepared by Seth et 
al. using reverse phase evaporation method [16]. The an-
tiviral efficacy of topical liposomal gel was tested; the 
relevant result revealed that this new formulation had 
improved therapeutic efficacy in treating herpes simplex 
virus type 1 and 2 infections [17]. Ramana et al. devel-
oped a liposomal nano delivery system for nevirapine. 
Nevirapine, a newly licensed drug, was the first member 
of non-nucleoside reverse transcriptase inhibitors. It has 
demonstrated potent activity against Human Immunode-
ficiency Virus type 1 (HIV-1).
The obtained results demonstrated that the encapsula-
tion efficiency was elevated. Another advantage of nev-
irapine-loaded liposomal nano delivery was improving 
the targeted delivery of antiretroviral drugs with fewer 
adverse effects [18]. Coating the external surface of lipo-
somes with Polyethylene Glycol (PEG) reduces immu-
nogenicity and the percentage of uptake by macrophages 
and leads to a prolonged blood circulation half-life. 
Therefore, pegilation provides enough time for them to 
leakage through endothelium towards the tissues [19]. In 
addition to paginated liposomes, stimuli responsive lipo-
some and targeted liposomes are also being developed. 
Immunoliposomes
Immunoliposomes are examples of targeted delivery 
technologies and have been extensively investigated for 
their potential in targeted drug delivery methods [20]. 
The aim of developing targeted liposomes is to selective-
ly deliver the cargo to target cells. Targeted liposomes 
are therefore designed to counterbalance the broad body 
distribution of stealth liposomes. The membranes of tar-
geted liposomes are functionalized with glycoproteins, 
polysaccharides, or ligands for specific receptors that 
cause the accumulation of liposomes in particular tis-
sues; thus, the liposome cargo can be preferentially re-
leased in target sites [20].
Another strategy to deliver the drug or antigen trans-
ported by liposomes in the desired site is represented by 
immunoliposomes. Antibodies and antibody fragments, 
as targeting moieties for liposome, are highly specific 
for the target antigens and combined antibody [20]. An-
tibodies can be attached to the surface of the liposomes 
and form valid specific binding to the specific site of 
target cells in vitro; however, their in vivo performance 
is often inefficient due to enhanced uptake through RES 
[21]. Examples of stimuli-responsive liposomes are the 
pH-responsive, redox-responsive, enzyme–responsive, 
and light-responsive liposomes, which keep their cargo 
encapsulated at body condition, but specifically dis-
charge it in the target site [22].
Many liposome formulations are available for treating 
viral infections in clinical use. Liposome encapsulated 
antivirals (e.g.  ribavirin, azidothymidine, or acyclovir) 
have been formulated and reported to reduce toxicity; 
today, these formulations are evaluated through more 
precise tests which are related to their efficacy [23]. 
Liposomal capability to induce immune responses to 
antigens bound to it was first reported by Gregoriadis 
and Allison [24]. Liposomes and virosomes have be-
come such important carrier systems that motivation 
for liposome-based vaccines significantly has increased 
in vaccine delivery. Virosomes are liposomes prepared 
by the fusion of natural or synthetic phospholipids and 
virus phospholipids, viral glycoproteins, or other viral 
proteins [25].
Epaxal is the first liposomal vaccine, used for hepa-
titis A prevention. Its formulation has been developed 
and patented by CrucellBerna Biotech, in Switzerland. 
This formulation is free of aluminum and thiomersal; 
therefore, has high tolerability and fewer adverse local 
effects compared with conventional aluminum-adsorbed 
vaccines. Epaxal is highly effective after the first dose 
administration, but can protect immunity for a limited 
time. Following the second dose, the immune system 
will be boosted up for the next 20 years [26]. Inflexal V 
is composed of haemagglutinin surface molecules of the 
influenza viruses. It was developed and patented by the 
CrucellBerna Biotech, in Switzerland.
These virosomes contain globular and unilamellar ves-
icles with an approximate diameter of 150nm. The im-
munogenicity and tolerability of Inflexal V vs. conven-
tional flu vaccines have indicated statistically significant 
improvements [26].
Polymeric nanoparticles
Polymeric nanoparticles are designed in two ways. In 
the first form, the drug molecule is entered into a cav-
ity and surrounded by a polymeric membrane, known as 
nanocapsule. In the second form, the drug is uniformly 
mixed with polymeric matrix, which is known as nano-
sphere (Table 1) [27]. The most common polymer, which 
is extensively used as a carrier for polymeric nanopar-
ticles, is Poly Lactic Acid Co Glycolic Acid (PLGA). 
PLGA, because of its biocompatibility and biodegrad-
ability, is a Food and Drug Administration (FDA) ap-
proved polymer. It provides an excellent delivery carrier 
Fasili Z, et al. Nanoparticles in the Treatment of Viral Infections and Toxicological Considerations. PBR. 2019; 5(4):1-20.
D
ow
nl
oa
de
d 
fro
m
 p
br
.m
az
um
s.
ac
.ir
 a
t 1
7:
33
 +
03
30
 o
n 
Th
ur
sd
ay
 J
an
ua
ry
 3
0t
h 
20
20
4 December 2019. Volume 5. Number 4
for the controlled administration of drugs, peptides, and 
proteins. PLGA, as a copolymer, consists of Poly Lactic 
Acid (PLA) and Poly Glycolic Acid (PGA) [28]. 
Polymeric nanoparticles immigrate into the cell 
through the endocytosis process. Phagocytosis, pi-
nocytosis, receptor-mediated endocytosis, and clath-
rin-mediated endocytosis are endocytosis pathways 
by which these systems can be taken up. Polymeric 
nanoparticles, like liposomes, are rapidly taken up by 
the RES in the parent or opsonized form; this results in 
limited contact time with their target organs in systemic 
circulation [29]. To prevent their uptake, various coat-
ing agents or shielding are used. This goal can also be 
achieved by some other solutions, such as modifying 
surface, decreasing these nanoparticles’ size, and exert-
ing hydrophilic molecules, like PEG [30].
Polymeric nanoparticles are useful systems for drug 
delivery and drug targeting. They can deliver drugs 
to specific sites, and help to improve the solubility of 
poorly soluble drug molecules. Compared to traditional 
formulations, polymeric nanoparticles have better ap-
plications and more effective drug delivery. This would 
ultimately improve treatment outcomes and patients’ 
compliance [31]. These specific properties prevent 
the rapid clearance of drug compounds and increase 
their stability. In turn, that makes the administration of 
drugs at lower doses possible, i.e.  essential in reducing 
drugs’ toxicity [10]. 
A significant number of scientific researchers reported 
using polymeric nanoparticles to deliver antiviral medi-
cines. Shibata et al. studied PLGA nanoparticles that con-
tain a combination of three Antiretroviral drugs (cART 
NPs) for the inhibition of HIV-1 replication. PLGA, as 
a biocompatible and biodegradable polymer, Encloses 
defavirenz (EFV) and boosts lopinavir (lopinavir/ritona-
vir; LPV/r). The average size of cART NPs was equal to 
55.4-138.3 nm and its average surface charge was calcu-
lated as -13.7–4.5 mV. These results suggested that all 
the three antiretroviral drugs are efficiently encapsulated 
(˃79%) into the cART NPs. The lack of cytotoxicity in 
the cell lines within 28 days in vitro with IC50 values in 
the nM range was investigated.
The relevant results revealed that the cART NP for-
mulation has more advantages with the equal amounts 
of the drugs orally administered to patients with HIV-1 
infection. Compared to the soluble antiretroviral drugs, 
this study demonstrated significant increase in the up-
take of the cARTNPs and higher levels of antiretrovi-
ral drugs in the nuclear, cytoskeleton, and membrane 
fractions of cells. This experiment demonstrated that 
the higher intracellular antiretroviral drug delivery by 
PLGA NPs formulation significantly reduces the HIV-1 
infectivity by inhibiting HIV replication at lower doses 
[32]. In a study, Guedj et al. applied the PLGA-based 
nano polymer as an efficient and safe carrier to increase 
the transport of active molecules into human monocyte-
derived macrophages.
They developed PLGA NPs containing bovine serum 
albumin (size =126 nm, zeta potential =−5.61 mV) 
which were taken up rapidly and efficiently by macro-
phages for the prevention and elimination of intracellular 
pathogens, like HIV. They concluded that PLGA NPs are 
swallowed by macrophages within 30 minutes. Further-
more, electron microscopy revealed they are found into 
the cytoplasm of human monocyte-derived macrophages 
after 45 minutes following administration. Several stud-
ies have documented that the use of polymeric-based 
nanocarriers is a promising strategy to deliver drug 
compounds in human monocyte-derived macrophages. 
Moreover, it could be beneficial in targeting pathogens 
that amplify inside macrophages such as HIV, malaria, 
visceral leishmaniasis, and tuberculosis [33].
Machado et al. tested PLGANPs contained Tenofovir 
(PLGA-TFV-NPs) embedded into a thin polymeric film 
base to allow the vaginal administration. PLGA-TFV-
NPs were prepared by a double emulsion solvent evapo-
ration method, and the encapsulation efficiency of TFV 
was high. The mean diameter value of nanoparticles was 
equal to 127nm, and the drug encapsulation efficiency 
was above 50%. The films containing TFV-loaded NPs; 
however, demonstrated two release steps, as follows: at 
first 15 min, 30% of TFV was detected in media because 
of an initial mild burst effect, which was followed by ap-
proximately linear sustained release.
In particular, both in vitro drug release profiles for 
TFV-loaded NPs films are favorable to potentially allow 
immediately; they also sustained TFV levels in the va-
gina. The described mouse model was used for the first 
time in the evaluation of vaginal films and corroborated 
the safety of PLGA- TFV/Stearyl amine NPs in films. 
This new formulation can be considered as an interesting 
substitute to currently used TFV gels in clinical sttings, 
if in vivo testing such as pharmacokinetics, safety and 
efficacy is justified. This film could be an appropriate al-
ternative to rings; the only difference is that the film has 
the advantage of being suitable for women in need of 
only occasional protection [34].
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Nanosuspensions
Nanosuspensions are the highly fine colloidal disper-
sions of nanoparticles stabilized by surfactants and poly-
mers. They are also recognized as a biphasic system, 
consisting of drug nanoparticles with the mean diameter 
values of <1 µm, dispersed in an aqueous vehicle [35]. 
Nanosuspensions consist of the poorly water-soluble 
drug molecules without any matrix material suspended 
in dispersion [36]. This nanotechnology can enhance the 
solubility of poorly water-soluble drug molecules. This 
approach is not only useful for molecules with poor solu-
bility but also poorly permeable drug compounds; this is 
a significant challenge for the formulators [37]. 
Nanosuspensions containing antiviral agents have been 
taken up by macrophages and showed time-dependent 
kinetics. Because of their nanosized form, they can 
quickly enter the cell. For increased uptake, their surface 
can be modified; that results in their specific receptor-
mediated cellular endocytosis, which in turn leads to 
increased drug concentration inside cellular compart-
ments. The suspensions can also be lyophilized and con-
verted into a solid matrix [10]. Dash et al. studied the 
nanosuspensions of atazanavir, ritonavir, and poloxamer 
188 as stabilizers obtained by high-pressure homogeni-
zation for neuroprotection in a humanized HIV infect-
ed animal model (nonobese diabetic/severe combined 
immunodeficiency-γcnull mice).
This formulation was administered intravenously and 
weekly, leading to the development of neuroprotective 
reaction (diagnosed by reduced neuronal, synaptic, and as-
trocyte damage). In addition, it decreased the viral loads 
and remained CD4+ cells in peripheral blood [38]. Roy et 
al. applied the same in vivo model and authenticated these 
findings; they correlated their relation with the tissue and 
blood serum levels of atazanavir, efavirenz, and ritonavir 
when these drugs were administered as nanosuspensions. 
Their data indicated that the nanoformulations of protease 
inhibitors show high efficacy in cell-line.
This model can be successfully used in the animal 
model of HIV-1 disease to stop CD4 + T cells loss and 
reduce viral replication [39]. These studies endorsed the 
role of monocytes/macrophages in the enhanced CNS 
delivery of the antiretroviral drug compounds. Shegokar 
et al. prepared nevirapine nanosuspensions by cold high-
pressure homogenization technique. Their surface prop-
erties were modified by the addition of surface modifi-
ers, such as serum albumin, PEG 1000, and dextran 60.
Their trial resulted in the production of nanoparticles 
with mean particle sizes of 515.8 nm, 520 nm, and 520.3 
nm, respectively. The nanosuspensions were easily taken 
up by primary macrophages, and indicated time-depen-
dent uptake kinetics. Nevirapine-loaded surface modi-
fied albumin nanosuspensions could pass through the 
blood brain barrier and accumulate in the brain for ˃24 
h. This is one of the major problems in treating Acquired 
Immune Deficiency Syndrome (AIDS). Thus, this find-
ing can generate a new perspective for treatment of HIV-
1 infection. Nanosization of nevirapine can significantly 
improve its in vivo behavior; additionally, it can poten-
tially target the infected cells [40].
Nanoemulsions
Nanoemulsions are colloidal particulate systems with 
10 to 1000 nm sizes, transporting drug molecules. An 
emulsion is a water and oil biphasic system where one 
phase is dispersed in the other. Macroemulsions are ther-
modynamically unstable systems; in these cases, they 
can be used as an emulsifying agent for its stabilization. 
In contrast, nanoemulsions, due to the presence of sur-
factants and co-surfactants, are more stable. Because of 
their small size, nanoemulsions are transparent. Nano-
emulsions are divided into three categories, as follows: 
first, oil is dispersed in the continuous aqueous phase 
and forms oil in water nanoemulsion; (b) second, water 
droplets are dispersed in oil phase and make water in oil 
nanoemulsion, and the third form is bi-continuous nano-
emulsions [41].
Hobson et al. described the controlled radical polymer-
ization synthesis of an amphiphilic branched copolymer, 
enable to stabilize nanoemulsions and dissolve efavi-
renz, and lopinavir as anti-HIV drug compounds. This 
process leads to increased drug absorption and a subse-
quent decrease in the required oral dose for treating HIV 
patients. To evaluate the antiviral activity of nanoemul-
sions, MT4 cells are infected with the Human Immuno-
deficiency Virus 1, strain IIIB (HIV-1) virus. 
The experiment is designed in the presence of the cells in 
which the virus replicates. Therefore, to show the effect of 
efavirenz, the drug should enter the cell and harness more 
proliferation of the virus. The MTT assay is performed to 
evaluate the cell viability of all cells in culture against HIV, 
leading to cell death. Unloaded nanoemulsion suggested 
no inherent antiviral activity against HIV-1 IIIB expected 
[42]. However, the drug-loaded nanoemulsion samples ef-
ficiently inhibited the HIV-1 IIIB cells.
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Dendrimers
Dendrimers are nanoscale carriers with symmetric 
molecules, homogeneous, and monodisperse struc-
tures, which have branches like a tree [43]. Dendrimers 
are monodisperse macromolecules containing a small 
molecule or a linear polymer in core and symmetrical 
branches around itself [44]. Polyconicdendrimers have 
no persistent shape and may change in size, shape, and 
flexibility as a function of increasing generations [45]. 
Dendrimers are hyperbranched macromolecules which 
their end-groups can be functionalized. As a result, their 
biochemical activity can be modified [46].
Dendrimers have unique features, allowing them to be 
variously applied. Dendrimers are defined as artificial 
macromolecules, containing several functional groups 
and a highly-branched structure [43]. Dendrimers are 
essential in molecular chemistry because of their high 
functional groups. This ability is named as host-guest 
property, i.e. based on the reaction of functional group of 
substrate molecule (guest) to a receptor molecule (host) 
[47]. Dendritic polymers have advantages in biomedical 
applications. They are analogous to proteins, enzymes, 
and viruses; therefore, their application is convenient. 
Dendrimers and other molecules can either be attached to 
the periphery or encapsulated in their interior voids [48].
Vacas-Cordoba et al. explained the mechanism of poly-
anionic carbosilanedendrimers G3-S16 and G2-NF16 
inhibiting HIV-1 infection. They demonstrated that the 
formulation prevented the infection of the cells by the 
HIV-1 at the first step. Carbosilanedendrimers can pre-
vent the binding of virus particles to target site. This 
process occurs through the occlusion of the gp120-CD4 
interaction. G3-S16 and G2-NF16 are polyanionic mol-
ecules, and their mechanism relates to the electrostatic 
interactions of their functional groups and proteins of the 
HIV-1envelope, like gp120.
That finally blocks target points and prevents virus 
binding to the target sites. They argued that dendrimers 
can also bind to some structures, like proteins at the cell 
surface; i.e.  related to the HIV-1 infection, including 
CD4 or CCR5 coreceptors. In addition, they reported 
dendrimers inhibit cell-to-cell HIV-1 transmission and 
complicate the formation of infectious synapse. In case 
of donor dendritic cell treatment, most dendritic cells 
containing HIV-1 diffused into the cytoplasm; whilst an 
increase of dendritic cells containing the HIV-1 in the 
intracellular sac-like compartment was observed when 
receptor cells were treated.
They hypothesized that it may be related to a different 
inhibitory mechanism of dendrimers in each case. They 
assumed that dendrimers would be preventing the spe-
cific protein interactions at the cell-to-cell contact area; 
thus, they block the correct signaling pathways for syn-
apse formation. Dendrimers can importantly affect the 
primary steps of HIV-1 infection in a multifunctional 
manner; therefore, their combination with other anti-
HIV-1 drug compounds could be interesting to generate 
new potent combinatorial microbicides [49].
Sepúlveda-Crespo et al. reviewed important role in pre-
venting HIV/HSV-2 (herpes simplex viruses) co-infec-
tion. Accordingly, they recommended new therapeutic 
options to manage individuals harboring multidrug-resis-
tant viruses. To improve the microbicide pharmacoki-
netics, better targeting, and innovative approaches, with 
a decreased chance for the development of resistance, 
nanotechnology-based microbicides, and especially den-
drimers, seem to be efficient strategies. The polyanionic 
dendrimers have shown exciting features for clinical use 
as antivirals against HIV/HSV-2 co-infection and other 
sexually transmitted infections. Polyanionic dendrimers 
have biocompatible, biodegradable, and monodispersed 
structures. This nanostructure can entrap several drug 
compounds by encapsulation or electrostatic interactions.
Furthermore, it can target specific sites and deliver drug 
compounds (e.g.  inside the cell). Polyanionicdendrimers 
have proper biological stability and can mimic biologi-
cal receptors or cofactors by surface modifications. Most 
of the development of resistance occurs spontaneously 
because of the high mutation rate of the virus. However, 
if viruses overcome the inhibitory effects of dendrimers 
through mutations, dendrimers can interact with other 
specific sites of gp120, and therefore inactivate the vi-
ruses. The majority of dendrimers can target the variabil-
ity of HIV/HSV-2 envelope proteins. 
This process would explain the susceptibility of dif-
ferent HIV and HSV-2 variants to these inhibitory 
nanoparticles. Molecular modeling systems can de-
velop optimized anti-HIV/HSV-2 dendrimers. A den-
drimer with dual action against viral infections will 
reduce the cost of therapy. This is due to its main ad-
vantage that can prevent both HIV and HSV-2 virus 
infections. There are some other dendrimers with dual 
antiviral activity, including SB105-A10, SPL7013, and 
even several carbosilanedendrimers [50].
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Solid Lipid Nanoparticles
Solid Lipid Nanoparticles (SLNs) were developed 
since 1990 as a substitute carrier system to liposomes, 
emulsions, and polymeric nanoparticles. SLNs are pro-
duced by replacing the liquid lipid (oil) of an o/w emul-
sion by a solid lipid or a blend of solid lipids, i.e.  the 
lipid particle-matrix being solid at room and body tem-
peratures [51].They have an average size of 40-1000 nm 
and a spherical morphology [52]. Gupta et al. revealed 
the solid lipid nanoparticles of efavirenz. They prepared 
those by high-pressure homogenization and solvent 
evaporation methods. In this study, the sizes of the aver-
age nanoparticles were <110 nm.
Such findings illustrated this formulation is suitable for 
administration through different routes. This is because 
it increases the permeability and bioavailability of the 
poorly soluble drug efavirenz. The intranasal formula-
tion of efavirenz demonstrated 150 times more efficient 
to reach the brain targeting and 70 times better absorbed, 
in comparison to the traditional formulation (capsule). 
Therefore, this novel formulation has higher potency for 
reducing the viral levels in plasma with a low dose of 
efavirenz; it has less toxicity as well as significant po-
tential to target the brain. Thus, this new formulation has 
a high potential to eradicate HIV reservoir and improve 
AIDS according to the clinical trials [53].
Penumarthi et al. developed a new SLNs formula-
tion as a non-viral Deoxyribonucleic Acid (DNA) vac-
cine delivery system. They prepared SLNs by solvent 
emulsification method and DNA–SLN complexes were 
prepared at different mass ratios. The synthesized SLNs 
indicated an average 110 nm hydrodynamic size with a 
Polydispersity Index (PDI) of 0.5. They concluded this 
system might be an excellent model for the non-viral de-
livery of DNA. This result could be a basis for future 
research in DNA vaccine delivery [54]. 
Niosomes
Niosomes are structurally similar to liposomes. They 
are composed of microscopic lamellar bilayer vesicles. 
Their difference with liposomes lied on their compo-
sitions, which non-ionic surfactants are using for pre-
paring niosomes. Therefore, niosomes are more stable 
and cost-effective, and their maintenance is more ac-
cessible. Some energy is required for heat and physical 
agitation to form this structure. In the bilayer structure, 
the hydrophilic heads are in contact with the aqueous 
solvent, whereas hydrophobic parts are oriented away 
from the aqueous solvent [55, 56]. Niosomes might be 
unilamellar or multilamellar, relying upon the tech-
nique used to set them up [57].
Sherry et al. studied the new formulation-niosome gel, 
containing acyclovir for enhancing dermal deposition. 
The highest percentage entrapment efficiency was in the 
vesicle size of 28 nm. The observed data suggested a 
greater permeation of niosomes across the skin from this 
formulation. They assumed the best ratio as span 60 and 
tween 60 as well as between cholesterol and lecithin as 
1:3 and 1:2, respectively in the niosome gel formulation. 
Therefore, different ratios of surfactants, cholesterol, and 
lecithin have been formulated and evaluated. Their opti-
mum ratios majorly impacts the control of permeation 
and skin penetration from the vesicles.
Localization of drug inside the derm or epiderm can pro-
vide effective concentrations in the skin while avoiding 
the systemic exposure. Drug delivery from the skin depot 
site in a sustained and controlled rate can be bioavailabil-
ity improved; therefore, they could control the disease for a 
prolonged period, compared to conventional dosage forms 
[58]. All mentioned above nanocarriers for drug delivery of 
antiviral agents are presented in Table 1. 
Toxicological consideration 
Role of nanoparticle characterization in toxicity 
Considering the importance of nanoparticles in estimat-
ing toxicological endpoints, accurate identification, and the 
characterization of nanoparticles are essential. Otherwise, 
the obtained toxic effects cannot easily be attributed to a 
particular property of the nanoparticles [59]. Internationally 
suitable protocols and standards for identifying the property 
of nanoparticles have not been implemented. Therefore, 
due to the lack of toxicity databases and proper character-
ization techniques, the toxicity effect evaluation of nanopar-
ticles is very hard. Different toxicity of nanoparticles relates 
to the function of their chemical structure or deposition site 
in human body [60].
Regarding the chemical structure, nanoparticles classify 
into two hard and soft types.  The instances of hard nanopar-
ticles are metals, and non-metal compounds and soft mate-
rials include dendrimer-, latex-, polymer- and protein-based 
nanoparticles [61]. To demonstrate the toxicity description 
of nanoparticles, different techniques have been applied. 
Electron microscopy is a precise method and is frequently 
applied to determine the different size, shape, and structure 
of particles. Bourdon et al. used animated light scattering 
and transition electron microscopy methods to assess the 
dynamic size of nanoparticles [62].
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Other identification procedures are centrifuge sedimenta-
tion and ultra-high light microscopy. These approaches have 
been applied in several studies for evaluating extensive col-
lections of nanoparticles, including carbon-based materials, 
metal oxides, metals, in cell culture and water media. Mur-
dock et al. used these methods in many of their research 
studies [63]. In many articles, for determining the Au content 
in HeLa and A594 cells when exposed to oligonucleotide-
modified Au nanoparticles from inductively coupled plasma 
mass spectrometry (ICP-MAS) has been used as an identi-
fication probe [64].  Another highly applicable technique is 
fluorescence spectroscopy. This method was used to identify 
the dynamic tracking of nanoparticles in cells [65]. In conclu-
sion, considering the different methods and characteristics of 
nanoparticles, a precise evaluation about the side effects of 
particles is only possible through conducting various studies 
about the nanoparticles’ properties [66].
Dose and dose criterions in toxicity 
The dose is explained as the quantity of a substance 
that will reach a biological system and affect the target 
organ. Dose determination is among the main factors in 
toxicology studies. In nanotoxicology surveys, the dose 
Table 1. Possible nanocarriers used in viral infections with structure and loaded drugs   
Structure  CargoNanocarriers
Ivermectin
Nevirapine
Liposomes
Epaxal®
Inflexal® V
Immunoliposomes
Defavirenz
Lopinavir
Tenofovir
Polymeric nanoparticles
Nevirapine
Atazanavir
Ritonavir 
Poloxamer 188
Nanosuspensions
Efavirenz 
Lopinavir
Nanoemulsions
G3-S16 
G2-NF16
Dendrimers
Efavirenz 
Non-viral DNA vaccine
Solid lipid nanoparticles 
AcyclovirNiosomes
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is directly calculated by the concentration of substance 
in different mediums (e.g.  air, food, & water) multiplied 
by the contract duration. The dose determination is vi-
tal to describe conclusions obtained from in vitro and 
in vivo studies for assessing health risks [67]. Although 
this definition may seem easy and straightforward, dose 
determination has many complexities. This is because 
various nanoparticle has different properties, such as 
size, surface chemistry, and diverse structure, which can 
change particle-particle (e.g.  aggregation) or particle-
cell (e.g.  uptake rates) interactions [68].
Toxicity analysis, to achieve a biological response, 
should be performed by considering doses in real condi-
tions. In nanotoxicology studies, dosing is expressed in 
two levels; high doses and low doses. High doses are 
useful in short contact for explaining mechanisms. Al-
though this parameter can be improper to predict the pro-
cess of human pathology from environmental contacts 
[69]. Moreover, low doses can be precise and sensitive 
in prolonged contact for inhalation experiments and are 
more likely to be predictive of human dangers [70].
Surface reactivity of nanoparticles and toxicity 
potential 
Regarding the surface properties of particles, toxicity 
studies about particles with similar physicochemical struc-
tures have demonstrated that severe toxicity occurs from 
smaller particles compared to larger ones [71]. Increased 
surface area is proportional to increased chemical reactivity. 
Therefore, immediately after receiving similar mass doses, 
including billions of nanoparticles to human body, it will 
respond very differently to contact with the biological sys-
tems [72]. In addition, when certain particles move into 
biological or environmental contexts, smaller structures, 
such as atoms, molecules, or macromolecules adjoin to the 
particle’s surface to form strong or weak bonds.
Some studies used titanium dioxide particles in mice; their 
obtained results suggested that nanoparticles with diameters 
of about 20nm create much higher inflammatory responses, 
compared with larger nanoparticles with mean diameters of 
250nm for a similar mass dose [73]. It has extensively been 
reported that nanoparticles in biological or environmental 
mediums never consist of “bare” particles [74]. There are 
comprehensive research studies available on the particles’ 
surface; however, because of their different properties, it 
seems necessary to perform more studies about physical 
and chemical characteristics of nanoparticles when deter-
mining their biological activities [75].
Comment mechanisms in the toxicity of 
nanoparticles  
Data are scarce about the metabolism of nanoparti-
cles. Due to the existence of different breakdowns of 
nanoparticles and unpredictable molecular responses, 
their degradation processes in the body when contact-
ing with biological systems are critical and different. 
Various protocols have suggested measuring particle 
uptake proportion and intracellular distribution in dif-
ferent cells [76]. The activity mechanisms of nanopar-
ticles when entering the cell and interacting with sub-
cellular structures divide into chemical or physical 
types. The primary chemical mechanism is the forma-
tion of Reactive Oxygen Species (ROS) [77].
In vivo and in vitro studies have reported that ROS 
production is a crucial factor in primary and second-
ary processes that can cause cell damage that function 
(by the peroxidizing of lipids, altering in proteins, dis-
rupting to DNA, interfering with signaling functions, 
and modulating gene transcription) and even cell death 
[78]. The other cases of chemical mechanisms are as 
follows: the activity and release of toxic ions [79], 
the disturbance of electron chain /ion cell membrane 
transport activity [80], catalysis damage [81], lipid per-
oxidation [82], and surfactant properties [83]. Physi-
cal mechanisms include damages membranes [83], 
changed membrane function [72], modified transport 
processes [84], and protein conformation/folding [85].
Chemical and physical mechanisms constitute several 
responses. These responses may occur before or after the 
contact of particle with organ targets. Wang et al., in an 
in vivo study, indicated once the nanoparticles enter the 
human body via different pathways, such as ingestion, 
dermal, and inhalation, nanoparticles’ metabolism occurs 
in blood circulation; then, their profiles clear in organs, 
such as the lung, liver, and kidney [86]. Therefore, in ad-
dition to identifying mechanisms, patterns clearance of 
nanoparticles in organs are important for understanding 
their fate in the body.
Cell toxicity of nanoparticle
Describing the cytotoxicity of nanoparticles is ben-
eficial for the accurate interpretation of their biological 
activities. However, identifying the proper molecular 
mechanisms underlying cell toxicity plays an essential 
role in the cytotoxicity of nanoparticles [87]. Several 
studies have reported the cytotoxicity of particles may 
be affected by their small size and surface in terms of 
cellular processes and numerous disease developments 
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[88]. Bahadar et al. evaluated the cytotoxicity effects 
of different nanoparticles using tetrazolium-based tech-
niques, such as MTT and MTS.
They exposed different cells, like cancer cell lines to 
nanoparticles with different compositions and sizes to 
determine cell viability. They concluded that these pa-
rameters (size and composition) primarily affect the de-
termination of intracellular responses, the degree of cy-
totoxicity, and the potential mechanisms of toxicity [89]. 
Lanone et al. investigated the cytotoxicity effects of 24 
nanoparticles with similar spherical diameter, and vari-
ous elemental compositions and structure on 2 important 
pulmonary cell lines; THP-and 1A549.
They found that copper- and zinc-based nanoparticles 
appeared to be the most toxic ones, compared with other 
samples. Titania-, alumina-, ceria-, and zirconia-based 
nanoparticles revealed moderate toxicity, and no toxicity 
was observed for tungsten carbide [90]. Uboldi et al. sur-
veyed the different cytotoxicity effects of SiO2 nanopar-
ticles using MTT assay and fluorescence microscopy on 
Balb/3T3 mouse fibroblasts. They observed nanopar-
ticles that were exclusively located in the cytoplasmic 
district of cell had no cytotoxicity effect [91]. Results ob-
tained from different investigations on nanoparticles in-
dicated these components might be toxic in experimen-
tal conditions; however, further studies are required to 
access fresh internationally agreed of bias toxicological 
models. Therefore, it is difficult to interpret these data.
Liver toxicity of nanoparticle
The liver has been documented as a vulnerable and 
main organ involved in the metabolism and expulsion 
of xenobiotic compounds of the body. All compounds 
entering the body are sorted by the liver tissues before 
being allocated to various body parts. The liver has 
many advantages, such as its high blood flow speed, 
its exposure with different compounds, and its high 
metabolic activity. Many investigations have suggested 
nanoparticles are trapped by the reticuloendothelial 
system in the liver; therefore, hepatotoxicity testing 
is a famous experiment for the safety assessment of 
nanoparticle toxicity. Studies are limited to the hepato-
toxicity of nanoparticles in the liver.
Teodoro et al. used the liver cells line as an in vitro 
study model to determine the toxicity of AgNP particles 
in BRL3A rats. They observed remarkable reductions in 
mitochondrial function, increment in lactate dehydroge-
nase (LDH leakage speed from cells, the elimination of 
antioxidants and a rise in ROS production [92]. Gaiseret 
al. surveyed the level of inflammation and oxidative 
stress produced in the liver of female Wistar rats by Ag 
NPs. They found that Ag NPs were very toxic for hepa-
tocytes and created hepatocyte homeostasis by decreas-
ing albumin release levels [93].
Yang et al. evaluated hepatic cell toxicity and its im-
portant mechanism by exposing cells to SiO2 NPs in 
ICR mice. They indicated SiO2 NPs have a possible 
distribution into different liver cells, including Kupffer 
and hepatic stellate cells; finally, the process may lead 
to hepatics dysfunction as well as granuloma produc-
tion in the liver [94]. Various studies exploring the 
hepatotoxicity of nanoparticles demonstrated that these 
components might be talented hepatotoxins for human 
exposure. Nevertheless, these studies, because of using 
different models and methods for toxicity measurement 
are complex for data interpretation. In addition, consid-
ering the limited studies in this area, further investiga-
tions are required (Figure 1).
Kidney toxicity of nanoparticle
The kidney, similar to the liver, is among the vital tar-
get organs for nanoparticle toxicity and a primary organ 
for clearing them from the body. Rana et al. investigated 
the effects of exposure to CdSNPs (cadmium sulfide 
nanoparticles) by some mechanism (lipid peroxidation 
generation and H2O2 production) in the rats’ kidneys. 
Their observations highlighted impairments in proximal 
tubules, mitochondrial dysfunction, disorders in nuclear 
and ER (endoplasmic reticulum), and eventually reduc-
tions in alkaline phosphatase level from the brush border 
of proximal tubules [95]. Moisan, Brochard et al. eval-
uated the toxicity of Carbon Black (CB) and titanium 
dioxide nanoparticles using immunofluorescence assay 
in glomerular mesangial cell (IP15) and the epithelial 
proximal tubular of renal.
They demonstrated that immunofluorescence micros-
copy assay using latex beads revealed NP materials 
considering size, the cells internalized particles, and ac-
cumulation in the cell cytoplasm, significantly increased 
ROS production in IP15 and LLC-PK1 cells [96]. Lu 
Xiao et al. conducted studied the toxic effect of zinc 
oxide on podocytes and rats. The in vitro experiment 
revealed podocytes exposed to ZnO NPs, compared to 
controls demonstrated an intracellular increase of Reac-
tive Oxygen Species (ROS), apoptosis formation, de-
creased SOD value, and increased MDA level. Results 
obtained from in vivo investigations on adult male Wis-
tar rats decreased the activity of catalase and SOD in 
kidney cortex [97].
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Previous studies performed about particles’ toxic ef-
fects on kidney are partial and different. The outcome 
of these studies speculated that many nanoparticles, due 
to translocation and accumulation in the kidney, could 
induce nephrotoxicity in these organs. 
Dermal toxicity of nanoparticles
Skin is the largest and the widest organ and the possible 
path for entrance of many nanoparticles of environmental 
conditions and occupational exposure to the body. There-
fore, assessing health risks and dermal toxicity of them is 
important. Various parameters may influence the dermal 
absorption of nanoparticles. The metal-based nanopar-
ticles, such as nanosilver, nanogold, nanocapsules, nano-
crystals, liposomes, and solid lipid nanoparticles, due to 
certain advantages, including enhance solubility, affect 
the transparency and color of cosmetic products; thus, 
they have been extensively used by the cosmetic, phar-
maceutical, paint, and paper industries [98].
Additionally, owing to the minimal size of nanopar-
ticles, assessing their toxic effects following long-term 
dermal exposure forms an essential discussion in nano-
technology studies. Jianhong et al. investigated the 
penetration rate and toxicity of titanium dioxide (TiO2) 
nanoparticles on dermal tissues using in vitro and in 
vivo experiments. Their in vitro model trial revealed 
titanium dioxide cannot penetrate through the stratum 
corneum of dermal; however, the in vivo model pro-
vided different results. The latter trial indicated TiO2 
particles could enter the body through the skin, reach 
different tissues, and induce several pathological le-
sions in the central organs [99]. 
Jebali et al. studied the skin toxicity of different 
nanoparticles, including zinc dioxide, titanium oxide, 
magnesium oxide, silver, and gold. They applied Lactate 
Dehydrogenase (LDH) and Reactive Oxygen species 
(ROS) generation assays on Triglyceride (TG) of the 
skin. They found an increase in LDH release and ROS 
generation. Such decreases occurred with pristine metal 
nanoparticles that are associated with many health risks 
for humans [100]. Publications on the dermal toxicity 
of nanoparticles are scarce and complex. These studies 
documented that a certain nanoparticle may have dif-
ferent effects on the skin. However, these studies have 
used different models, tests and experimental conditions; 
thus, their achieved data are challenging to interpret.
 Pulmonary toxicity of nanoparticles
Inhalation is the only route of human exposure to air-
borne nanoparticles. After inhalation, the deposition of 
nanoparticles available in the air in different sections of 
the respiratory tract occurs by diffusion starting from the 
nose and pharynx, down to the lungs [101]. The depo-
sition process causes larger particles achieve biological 
tissues that would not frequently be accessed. For ex-
ample, TiO2 nanoparticles, by inhalation, translate into 
the lung texture of rats and mice and form inflammation 
[102]. Limited studies on the toxicity of nanoparticles 
Figure 1. Hepatotoxicity induced by nanoparticles according published studies  
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in pulmonary tissue reported its nontoxicity. Hong et al. 
investigated the influence of Silica Nanoparticles (SNs) 
on the lungs of rats to evaluate the toxicity and possible 
injury of SNs. Their results suggested SNs can make 
pulmonary fibrosis by increasing lipid peroxidation and 
high expression of cytokines [103].
Morimoto et al. performed studies about intratracheal 
instillation and inhalation of Zinc Oxide (ZnO) nanopar-
ticles to assay pulmonary toxicity. In the inhalation 
study, they found high concentration may increase total 
cell and neutrophil counts. In the intratracheal instilla-
tion study, in addition to the observations as mentioned 
above, their results revealed an increase in the expres-
sion of Cytokine-Induced Neutrophil Chemoattractant 
(CINC)-1, CINC-2, chemokine for neutrophil, and 
Heme Oxygenase-1 (HO-1), an oxidative stress marker 
in the BALF [104]. Loret et al. evaluated biological re-
sponses (pro-inflammatory effects and quantitative com-
parisons) caused by poorly soluble and toxic TiO2 and 
CeO2 nanoparticles through in vivo and in vitro methods, 
using compatible dose metrics.
They found that more advanced detection techniques 
could enhance prediction ability about the pulmonary 
toxicity of toxic TiO2 and CeO2 nanoparticles [105]. Dif-
ferent studies have been conducted on the inhalation 
toxicity of nanoparticles. The results of these studies 
indicated that specific nanoparticles might be prone to 
induce harm in respiratory tract. However, the findings 
of these studies, because of using different methods for 
nanoparticles identification, are difficult to interpret.
 Gastrointestinal toxicity of nanoparticles
A possible route of nanoparticle entry to the body is the 
gastrointestinal tract. These components, in gastrointes-
tinal tract, operate directly through intentional ingestion 
and indirectly via nanoparticle dissolution from food 
containers. Evaluating nanoparticles in gastrointestinal 
tract is required not only due to absorption and accu-
mulation of them in this organ but also because of their 
potential role in altering gut microbes and the effects of 
this perturbation on the host. Waldman et al. explored dif-
ferent toxicities of nanoparticles (e.g.  zinc oxide, Silica, 
and titanium dioxide) to assay changes, such as necrosis, 
apoptosis, membrane damage, and mitochondrial activ-
ity on intestinal epithelial C2BBe1 cells.
They concluded that silica and titanium dioxide 
nanoparticles were nontoxic, although all nanoparticles 
were internalized by cells. Mild acute toxicity of zinc ox-
ide nanoparticles was observed after 24-hour treatment 
of intestinal epithelial. Thus, silica, titanium dioxide, 
and zinc oxide nanoparticles induced slight toxicity in 
intestinal epithelial cells [106]. The literature provides 
limited information on the gastrointestinal toxicity of 
nanoparticles. This information is controversial and in-
consistent. Such controversy and inconsistency may be 
due to the lack of proper characterization of the nanopar-
ticles, including their source and configuration. There-
fore, the data obtained from these studies are difficult to 
interpret.
Cardiotoxicity toxicity of nanoparticles
Our information about the toxicity effects of particu-
late available in air pollution as well as a gastrointesti-
nal tract on cardiovascular health is limited. Further-
more, this problem has involved numerous studies in 
toxicology. Miller et al. investigated the cardiovascu-
lar toxicity of gold nanoparticles in healthy volunteers 
using robust and accurate detectors like mass spec-
trometry and Raman microscopy. They evaluated dif-
ferent hematologic parameters, inflammatory factors, 
oxidative stress reaction, endothelial disorders, and 
myocardial enzyme dysfunction in serum samples. 
They expressed gold nanoparticles provided vascular 
inflammation in the studied sample.
Their results suggested that the cardiovascular toxic-
ity of gold nanoparticles had a direct relationship with 
particle size and dosage [107]. Beltrán et al. evaluated 
cardiomyocyte shortening and intracellular Ca+2 and 
disorder contractility and intracellular Ca+2 transient 
amplitude during adrenergic stimulation in exposure 
with SiO2 nanoparticles. Their results indicated SiO2 
leads to the depolarization of the mitochondrial mem-
brane, decreases ATP production, glutathione depletion, 
H2O2 generation, and increases oxidative stress and mi-
tochondrial dysfunction. They concluded that exposure 
to SiO2 nanoparticle is a potential risk factor for the car-
diovascular system [108].
Hussainy et al. evaluated the toxicity effects of alumi-
num oxide (Al2O3) nanoparticles on the different param-
eters of myocardial as electrical activities, morphology 
structure, inflammatory factors, and the myocardial ex-
pression of connexin 43 in rats. Their results suggested 
disorder in ECG, significant increase in Creatine Phos-
phokinase (CPK), Triglycerides (TGs), Cholesterol 
(LDL), and significant decreases in serum HDL and 
myocardial GSH, and Catalase (CAT). They concluded 
that aluminum oxide nanoparticles cause myocardial 
dysfunctions [109].
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There is limited study on the cardiotoxicity of nanopar-
ticles. Previous studies performed many investigations 
about nanoparticle properties, like their mechanism, 
which is vital for the cardiotoxicity identification of 
these particles. Additionally, because there are different 
experimental conditions for nanoparticle characteriza-
tion, the information obtained from these studies are 
hard to interpret. The effects of nanoparticles on humans 
and animals are illustrated in Figure 2.
Neurotoxicity of nanoparticles
Researchers have extensively indicated evidence that 
airborne NPs available in environmental or occupational 
exposure can penetrate to Blood-Brain Barrier (BBB), 
access to the brain through the olfactory nerve pathway, 
and finally cause injury by the induction of oxidative 
stress, inflammatory responses, and cytotoxicity. Studies 
on the CNS toxicity of nanoparticles are limited. Tian et 
al. investigated the neurotoxicity effects obtained by ex-
posure to zinc oxide nanoparticle in different-aged mice 
Figure 2. The cardiovascular toxicity effects of nanoparticles on humans and animals
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using field emission scanning electron microscope. They 
concluded in old mice, subsequent exposure to ZnO NP 
increases oxidative stress values, impair learning and 
memory, and change hippocampal pathological.
Therefore, their findings demonstrated zinc oxide 
nanoparticles could induce neurotoxicity [110]. Song 
et al. evaluated the neurotoxicity of Titanium Dioxide 
Nanoparticles (TiO2NPs) in different-rodents using in 
vivo and in vitro experiments. They investigated the 
morphology structure and function of glial cells. Their 
results indicated TiO2NPs might induce necrosis in 
cells, significant impair mitochondrial, lysosome, and 
cytoskeleton, and change the recognition ability, spatial 
memory, and learning ability in TiO2NPs-treated rodents. 
Therefore, their findings demonstrated titanium dioxide 
nanoparticle could stimulate neurotoxicity and neurode-
generation diseases [111]. Literature about the neurotox-
icity of nanoparticle is insufficient; therefore, to increase 
knowledge about the potential risks of nanoparticle on 
brain health, extensive studies are required (Figure 3).
Immunotoxicity of nanoparticles
Immunotoxicity is a new field emerging in nanotoxi-
cology. Reports on the immunotoxicity of nanoparticles 
are inadequate and inaccurate. The compatibility of 
nanoparticles with the immune system mainly depends 
on the physicochemical properties(e.g.  size, form, 
congestion state, chemical compound, surface area, & 
charge) that can stimulate or suppress the immune re-
sponse [112]. The reaction between nanoparticles and 
biological tissues or immune system can be via the gen-
eration of active oxygen species (oxidative burst) and 
the release of pro-inflammatory cytokines. This process 
leads to the production of responses, including the sup-
pression of immune system, increased sensitivity, immu-
nogenicity, and autoimmunity in the human body [113].
Studies have reported that TiO2 nanoparticle, via change 
in the signaling pathway of p38-Nrf-2, can significantly 
increase ROS accumulation in splenic and subsequent 
lipid peroxidation or HO-1 expression in cell [114]. Expo-
sure to silver nanoparticles with diverse sizes form ROS 
production, glutathione depletion, and inhibits superoxide 
dismutase enzyme [115]. Investigations suggested silica 
nanoparticle not only activates the MAPKs signaling 
pathway employing increased expression of phosphory-
lated JNK and p38 MAPK but also inactivates the Extra-
cellular Signal-Regulated Kinases (ERKs). This process 
leads to ROS production and oxidative stress that regulate 
apoptosis in cell. Data are scarce on the immunotoxicity 
of nanoparticles. Available investigations on the immune 
system toxicity of nanoparticle are limited. Therefore, it is 
necessary to conduct numerous studies for understanding 
the mechanisms associated with the side effects of par-
ticles on immune system (Figure 4).
Conclusion
Nanotechnology in drug delivery systems is a new meth-
od for confronting problems associated with conventional 
Figure 3. Neurotoxicity effects of nanoparticles 
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drug therapies, especially in antiviral drugs. Nanomateri-
als can improve pharmaceutical efficacy by optimizing 
the physical properties of antiviral drug compounds, as 
well as improving their bioavailability. Advancements in 
this field have led to targeted drug delivery, controlled re-
lease, or slow-release, reduced dosage, and drug toxicity, 
compared with conventional approaches. Nanotechnol-
ogy, especially in antiviral therapeutic agents, increased 
the permeability of poorly water-soluble drug compounds 
and the stability of unstable drugs.
Despite many advantages, these nanoparticles, com-
pared to conventional therapies, require more investiga-
tion regarding their toxic effects. Identifying the toxicity 
profiling and biological interaction of nanomaterials due 
to their natural present in the ecosystem environmental 
as well as the therapeutic use of their antiviral drug com-
pounds are essential. They may generate toxic effects on 
human exposure by many mechanisms, such as reactive 
oxygen species generation, protein misfolding, mem-
brane perturbation, and direct physical damage. Our 
knowledge about the safety of nanomaterials is limited.
Different studies have used in vitro and in vivo test 
models, different sources, and techniques in this regard. 
Therefore, their data are hard to interpret. However, the 
applications of nanomaterials in the nano-formulations of 
drugs require a different structure that balances their dis-
advantages versus their advantages and therapeutic ben-
efits. Due to the use of a wide range of nanoparticles, like 
nanomedicine and their undesirable effects on healthy 
human and environment caused many researchers to 
assess the toxicity of nanoparticles. The physicochemi-
cal properties of nanoparticles, including different size, 
form, morphology, and chemical structure are essential 
components, contributing to their side effects [73]. 
There are no appropriate toxicity tests for the safety 
evaluation of nanoparticles. National Center for Toxi-
cological Research and National Institute of Standards 
and Technology are the leading centers for studying 
nanoparticles; they have not reported a positive standard 
protocol for the toxicity testing of nanoparticles [67]. To 
increase performance, developing standard protocols for 
nanoparticles is necessary for expert investigators, appro-
priate laboratory conditions, proper experimental obser-
vations, and the accurate identification of nanoparticles. 
Therefore, extensive studies are required for increasing 
our general knowledge of toxicity tests and the effects of 
nanoparticles on biological systems and human health.
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